View clinical trials related to PNH.
Filter by:Patients who are positive of PNH-type cells are followed up for the percentage of PNH-type cells regularly for examining how it change.
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.
This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.
How does long term treatment with Soliris affect HAHA in PNH patients?